The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

Antipsychotic polypharmacy in psychotic disorders is widespread despite international guidelines favoring monotherapy. Previous evidence indicates the utility of low-dose partial dopamine agonist (PDAs) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lippi, Matteo, Fanelli, Giuseppe, Fabbri, Chiara, De Ronchi, Diana, Serretti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521590/
https://www.ncbi.nlm.nih.gov/pubmed/35815937
http://dx.doi.org/10.1097/YIC.0000000000000417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521590/
https://www.ncbi.nlm.nih.gov/pubmed/35815937
http://dx.doi.org/10.1097/YIC.0000000000000417

Ejemplares similares